De-escalation and stopping treatment in CML: final results

Previous results of the DESTINY study have shown high rates of recurrence-free survival (RFS) after one year of de-escalation and one year of stopping treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study included patients with a major molecular response (MMR but not MR4; 0,1%-0,01%) in addition to patients with a molecular response of grade MR4 (<0,01%). Dr Richard Clark (University of Liverpool, UK) presented the final results of DESTINY showing that the high rates of RFS are sustained in the second year of stopping. At 36 months follow-up the RFS was 72% in the MR4 group, and 39% in the MMR but not MR4 group. Clark: “The results suggest that initial de-escalation is not simply delaying recurrence.”

Visit the EHA Learning Center to view the abstract.

Last Updated on Thursday 02 August 2018.